MCID: ACR007
MIFTS: 66

Acromegaly

Categories: Rare diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Acromegaly

MalaCards integrated aliases for Acromegaly:

Name: Acromegaly 12 50 56 13 52 42 14 69
Growth Hormone Excess 50 29
Growth Hormone-Secreting Pituitary Adenoma 69
Somatotroph Adenoma 50
Pituitary Giant 50

Characteristics:

Orphanet epidemiological data:

56
acromegaly
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult;

Classifications:



Summaries for Acromegaly

NIH Rare Diseases : 50 acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (gh). it is most often diagnosed in middle-aged adults, although symptoms can appear at any age. signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. the condition is usually caused by benign tumors on the pituitary called adenomas. rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce gh. it is sporadic in 95% of the cases, but almost 50% of the childhood-onset cases have an identifiable genemutation, most commonly in the aip gene or gpr101 gene. treatment may include hormones, radiotherapy, and surgery. when left untreated, it can result in serious illness and premature death. when gh-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly.   acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, mccune-allright syndrome, neurofibromatosis or carney complex.  last updated: 2/10/2017

MalaCards based summary : Acromegaly, also known as growth hormone excess, is related to functioning pituitary adenoma and pituitary adenoma, prolactin-secreting, and has symptoms including macroglossia, acne and broad jaw. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are TGF-Beta Pathway and Peptide ligand-binding receptors. The drugs Octreotide and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and testes, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A disease of metabolism that has material basis in excessive growth hormone production which results_in enlargement located in limb.

Wikipedia : 72 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
id Related Disease Score Top Affiliating Genes
1 functioning pituitary adenoma 30.6 POMC SST
2 pituitary adenoma, prolactin-secreting 30.5 AIP CDH23 GH1 GNAS GPR101 IGF1
3 pituitary adenoma, growth hormone-secreting 11.9
4 x-linked intellectual disability-acromegaly-hyperactivity syndrome 11.8
5 pituitary adenoma, growth hormone-secreting 2 11.5
6 gigantism 11.2
7 pituitary tumors 11.1
8 g6pc3 deficiency 11.0 GH1 PRL
9 small cell lung cancer, childhood 10.9 IGF1 IGFBP3
10 acyl-coa dehydrogenase, short-chain, deficiency of 10.9 GHR IGF1
11 simple cryoglobulinemia 10.9 GH1 GHR SST
12 lipase deficiency, combined 10.9 GH1 IGF1 IGFBP3
13 selenium poisoning 10.8 IGF1 IGFBP3 INS
14 obesity, mc4r-related 10.8 GHRL GNAS
15 hyperlipoproteinemia, type ib 10.8 IGF1 IGFBP3 INS
16 oral leukoedema 10.8 SST SSTR2
17 glomerulosclerosis, focal segmental, 1 10.8 IGF1 IGFBP3 INS
18 genital dwarfism, turner type 10.8 PRL TRH
19 prolactin producing pituitary tumor 10.8 IGF1 POMC SST
20 porokeratosis 10.8 IGF1 INS PRL
21 ossification of the posterior longitudinal ligament of spine 10.8
22 mccune-albright syndrome, somatic, mosaic 10.8
23 dwarfism familial with muscle spasms 10.7 GH1 GHR GHRH
24 neuritis 10.7 SST SSTR2 SSTR5
25 african histoplasmosis 10.7 POMC PRL SST
26 nutritional optic neuropathy 10.7 GHRL SST
27 lymphoepithelioma-like carcinoma 10.7 POMC PRL SST
28 kowarski syndrome 10.7 GH1 GHR GHRH IGF1
29 primary hypomagnesemia 10.7 GH1 GHR GHRH IGF1
30 immune system organ benign neoplasm 10.7 IGF1 POMC PRL
31 actinobacillosis 10.7 POMC PRL SST
32 plague 10.7 IGF1 IGFBP3 PRL
33 olfactory nerve neoplasm 10.7 GHRH POMC PRL
34 osteoclast-like giant cell neoplasm of the pancreas 10.7 GHRH POMC PRL
35 trabecular follicular adenocarcinoma 10.7 POMC PRL SST
36 lymphoma, gastric non hodgkins type 10.7 GH1 POMC
37 bronchiectasis 10.7 POMC PRL SST
38 cutis laxa 10.7 INS POMC
39 cervical keratinizing squamous cell carcinoma 10.6 INS SST
40 sphingolipidosis 10.6 INS POMC PRL
41 periampullary adenoma 10.6 GHRL IGF1 INS
42 algoneurodystrophy 10.6 IGF1 IGF2 INS
43 extraskeletal ewing sarcoma 10.6 AIP MEN1
44 didymosis aplasticosebacea 10.6 AIP MEN1
45 hypothyroidism, congenital, nongoitrous 4 10.6 GH1 IGF1 POMC PRL
46 worth's syndrome 10.6 GH1 GNAS IGF1 PRL SST
47 traumatic glaucoma 10.6 IGF1 IGFBP1 POMC
48 spondylolysis 10.6 INS POMC PRL
49 ulcerative blepharitis 10.6 IGF1 INS POMC PRL
50 capillary lymphangioma 10.6 GH1 IGF1 INS POMC

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to Acromegaly

Symptoms & Phenotypes for Acromegaly

Human phenotypes related to Acromegaly:

56 32 (show top 50) (show all 58)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macroglossia 56 32 hallmark (90%) Very frequent (99-80%) HP:0000158
2 acne 56 32 occasional (7.5%) Occasional (29-5%) HP:0001061
3 broad jaw 56 32 frequent (33%) Frequent (79-30%) HP:0012802
4 migraine 56 32 frequent (33%) Frequent (79-30%) HP:0002076
5 long face 56 32 hallmark (90%) Very frequent (99-80%) HP:0000276
6 coarse facial features 56 32 hallmark (90%) Very frequent (99-80%) HP:0000280
7 kyphosis 56 32 frequent (33%) Frequent (79-30%) HP:0002808
8 fatigue 56 32 hallmark (90%) Very frequent (99-80%) HP:0012378
9 frontal bossing 56 32 frequent (33%) Frequent (79-30%) HP:0002007
10 hypertrophic cardiomyopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0001639
11 depression 56 32 frequent (33%) Frequent (79-30%) HP:0000716
12 broad forehead 56 32 hallmark (90%) Very frequent (99-80%) HP:0000337
13 full cheeks 56 32 hallmark (90%) Very frequent (99-80%) HP:0000293
14 hypertension 56 32 frequent (33%) Frequent (79-30%) HP:0000822
15 synophrys 56 32 frequent (33%) Frequent (79-30%) HP:0000664
16 osteoarthritis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002758
17 diabetes mellitus 56 32 frequent (33%) Frequent (79-30%) HP:0000819
18 tall stature 56 32 hallmark (90%) Very frequent (99-80%) HP:0000098
19 widely spaced teeth 56 32 frequent (33%) Frequent (79-30%) HP:0000687
20 acanthosis nigricans 56 32 occasional (7.5%) Occasional (29-5%) HP:0000956
21 hyperhidrosis 56 32 hallmark (90%) Very frequent (99-80%) HP:0000975
22 anxiety 56 32 frequent (33%) Frequent (79-30%) HP:0000739
23 impotence 56 32 occasional (7.5%) Occasional (29-5%) HP:0000802
24 cerebral palsy 56 32 frequent (33%) Frequent (79-30%) HP:0100021
25 arthralgia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002829
26 macrodactyly 56 32 hallmark (90%) Very frequent (99-80%) HP:0004099
27 sleep apnea 56 32 frequent (33%) Frequent (79-30%) HP:0010535
28 wide nose 56 32 hallmark (90%) Very frequent (99-80%) HP:0000445
29 hoarse voice 56 32 frequent (33%) Frequent (79-30%) HP:0001609
30 joint swelling 56 32 hallmark (90%) Very frequent (99-80%) HP:0001386
31 mitral regurgitation 56 32 occasional (7.5%) Occasional (29-5%) HP:0001653
32 large hands 56 32 hallmark (90%) Very frequent (99-80%) HP:0001176
33 spinal canal stenosis 56 32 frequent (33%) Frequent (79-30%) HP:0003416
34 thick lower lip vermilion 56 32 hallmark (90%) Very frequent (99-80%) HP:0000179
35 generalized hirsutism 56 32 frequent (33%) Frequent (79-30%) HP:0002230
36 paresthesia 56 32 frequent (33%) Frequent (79-30%) HP:0003401
37 macrotia 56 32 hallmark (90%) Very frequent (99-80%) HP:0000400
38 deep plantar creases 56 32 hallmark (90%) Very frequent (99-80%) HP:0001869
39 dysuria 56 32 occasional (7.5%) Occasional (29-5%) HP:0100518
40 deep palmar crease 56 32 hallmark (90%) Very frequent (99-80%) HP:0006191
41 palpebral edema 56 32 frequent (33%) Frequent (79-30%) HP:0100540
42 galactorrhea 56 32 occasional (7.5%) Occasional (29-5%) HP:0100829
43 mandibular prognathia 56 32 hallmark (90%) Very frequent (99-80%) HP:0000303
44 abnormality of the fingernails 56 32 frequent (33%) Frequent (79-30%) HP:0001231
45 anterior hypopituitarism 56 32 hallmark (90%) Very frequent (99-80%) HP:0000830
46 pituitary prolactin cell adenoma 56 32 frequent (33%) Frequent (79-30%) HP:0006767
47 long penis 56 32 hallmark (90%) Very frequent (99-80%) HP:0000040
48 generalized hyperpigmentation 56 32 occasional (7.5%) Occasional (29-5%) HP:0007440
49 tapered finger 56 32 hallmark (90%) Very frequent (99-80%) HP:0001182
50 abnormality of the toenails 56 32 frequent (33%) Frequent (79-30%) HP:0008388

MGI Mouse Phenotypes related to Acromegaly:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 AIP CDH23 GHR GHRH GHRL GNAS
2 endocrine/exocrine gland MP:0005379 10.28 POMC PRL SSTR5 TRH AIP GHR
3 growth/size/body region MP:0005378 10.25 AIP CDH23 GHR GHRH GNAS IGF1
4 behavior/neurological MP:0005386 10.24 CDH23 GHR GHRL GNAS IGF2 IGFBP3
5 cardiovascular system MP:0005385 10.18 AIP GHR GNAS GPR101 IGF1 IGF2
6 immune system MP:0005387 10.06 INS MEN1 POMC PRL SST GHR
7 adipose tissue MP:0005375 10.05 POMC GHR GHRL GNAS IGF1 IGFBP3
8 digestive/alimentary MP:0005381 10 CDH23 GHRL IGF2 INS MEN1 SST
9 integument MP:0010771 9.91 AIP GHR GNAS IGF1 IGF2 IGFBP3
10 liver/biliary system MP:0005370 9.9 INS MEN1 POMC PRL AIP GHR
11 nervous system MP:0003631 9.77 SST SSTR2 TRH CDH23 GHR GHRH
12 renal/urinary system MP:0005367 9.1 GHR GNAS IGF1 IGF2 INS POMC

Drugs & Therapeutics for Acromegaly

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
2 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
3
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
4
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Zinc Approved Phase 4 7440-66-6 32051 23994
9
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
10 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
12 insulin Phase 4,Phase 3,Phase 2
13 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
14 Mitogens Phase 4,Phase 3,Phase 2
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Complement Factor I Phase 4,Phase 3
19 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1
20 Antiparkinson Agents Phase 4,Phase 3
21 Autonomic Agents Phase 4,Phase 2,Phase 3
22 Dopamine Agents Phase 4,Phase 3,Phase 2
23 Dopamine agonists Phase 4,Phase 3
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
25 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
26 Protective Agents Phase 4,Phase 2
27 Pharmaceutical Solutions Phase 4
28 Hypoglycemic Agents Phase 4,Phase 2
29 Liver Extracts Phase 4
30 Dipeptidyl-Peptidase IV Inhibitors Phase 4
31 HIV Protease Inhibitors Phase 4
32 Incretins Phase 4
33
protease inhibitors Phase 4
34 Sitagliptin Phosphate Phase 4
35
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
36
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
37
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754 657311
38
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
39 Racepinephrine Approved Phase 2, Phase 3
40 Carboxymethylcellulose Sodium Phase 3
41 Edotreotide Phase 3
42 Radiopharmaceuticals Phase 3
43 Adrenergic Agents Phase 2, Phase 3
44 Adrenergic Agonists Phase 2, Phase 3
45 Adrenergic alpha-Agonists Phase 2, Phase 3
46 Adrenergic beta-Agonists Phase 2, Phase 3
47 Androgens Phase 2, Phase 3
48 Anesthetics Phase 2, Phase 3
49 Anesthetics, Local Phase 2, Phase 3
50 Anti-Asthmatic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 149)

id Name Status NCT ID Phase Drugs
1 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
2 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
6 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
7 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
8 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
9 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
10 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
11 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
12 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
13 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
14 Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Completed NCT01014793 Phase 4 cabergoline
15 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
16 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
17 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
18 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
19 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
20 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
21 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
22 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
23 Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery Completed NCT00500227 Phase 4
24 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
25 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
26 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
27 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
28 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
29 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
30 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
31 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
32 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
33 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
34 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide (SOM230);octreotide LAR 30mg;lanreotide ATG 120mg
35 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
36 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
37 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
38 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
39 Long Term Study With B2036-PEG Completed NCT00143416 Phase 3 Pegvisomant
40 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
41 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
42 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
43 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
44 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
45 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
46 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
47 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
48 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
49 Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
50 Strict IGF-1 Control in Acromegaly Recruiting NCT02952885 Phase 3 Pegvisomant

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

Genetic tests related to Acromegaly:

id Genetic test Affiliating Genes
1 Growth Hormone Excess 29

Anatomical Context for Acromegaly

MalaCards organs/tissues related to Acromegaly:

39
Pituitary, Bone, Testes, Brain, Skin, Lung, Pancreas

Publications for Acromegaly

Articles related to Acromegaly:

(show top 50) (show all 1520)
id Title Authors Year
1
Assessment of lung function in a large cohort of patients with acromegaly. ( 28432267 )
2017
2
The efficacy of medical treatment in patients with acromegaly in clinical practice. ( 28931779 )
2017
3
Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. ( 27932529 )
2017
4
Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1A levels following pituitary surgery in acromegaly. ( 28341329 )
2017
5
Letter to the Editor: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study". ( 28911159 )
2017
6
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
7
Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity? ( 28879648 )
2017
8
Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients. ( 28357781 )
2017
9
An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. ( 28469929 )
2017
10
Calcium and bone turnover markers in acromegaly: a prospective controlled study. ( 28407138 )
2017
11
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. ( 28368500 )
2017
12
Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients. ( 28332074 )
2017
13
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. ( 27896545 )
2017
14
Development of ACRODAT(Ar), a new software medical device to assess disease activity in patients with acromegaly. ( 28887782 )
2017
15
Acromegaly and bone. ( 28880058 )
2017
16
A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically. ( 28904276 )
2017
17
Assessment of Nasal Carriage of Staphylococcus Aureus and Axillar Flora in Patients With Acromegaly. ( 28060097 )
2017
18
Prevalence of acromegaly in patients with symptoms of sleep apnea. ( 28898247 )
2017
19
Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. ( 27913611 )
2017
20
Bone Material Strength index as measured by impact microindentation is altered in patients with acromegaly. ( 28077497 )
2017
21
Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly. ( 28465267 )
2017
22
Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: a case report. ( 28390105 )
2017
23
Acromegaly treatment in Romania. How close are we to disease control? ( 28879646 )
2017
24
GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment. ( 28490347 )
2017
25
Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. ( 28372573 )
2017
26
Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients. ( 28508245 )
2017
27
Fibroblast Growth Factor 21 in Patients with Acromegaly. ( 28931175 )
2017
28
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. ( 27932528 )
2017
29
Progress in the formulation and delivery of somatostatin analogs for acromegaly. ( 28944744 )
2017
30
Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly. ( 28469926 )
2017
31
Acromegaly determination using discriminant analysis of the three-dimensional facial classification in Taiwanese. ( 28871717 )
2017
32
Treatment of acromegaly patients at the Federal University of TriAcngulo Mineiro (UFTM): Experience Report. ( 28492721 )
2017
33
Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. ( 28913667 )
2017
34
Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center. ( 28874187 )
2017
35
Suffocation due to Thoracic Deformity Caused by Acromegaly. ( 28420845 )
2017
36
Body composition and ectopic lipid changes with biochemical control of acromegaly. ( 28945897 )
2017
37
Endoscopic Transsphenoidal Approach for Acromegaly: Remission Rates in 401 Patients: 2010 Consensus Criteria. ( 28887283 )
2017
38
HIGH-DOSE AND HIGH-FREQUENCY LANREOTIDE AUTOGEL IN ACROMEGALY: A RANDOMIZED, MULTICENTER STUDY. ( 28419317 )
2017
39
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. ( 28042644 )
2017
40
Persistent reduction of circulating myeloid calcifying cells in acromegaly. Relevance to the bone-vascular axis. ( 28323966 )
2017
41
The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens. ( 28402548 )
2017
42
Response to Letter: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study". ( 28911163 )
2017
43
Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use. ( 28951345 )
2017
44
Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. ( 27910111 )
2017
45
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. ( 28477735 )
2017
46
Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly. ( 28913579 )
2017
47
Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. ( 28592706 )
2017
48
Guidelines versus real life practice: the case of colonoscopy in acromegaly. ( 28936751 )
2017
49
Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. ( 27155600 )
2016
50
Coexistence of acromegaly with dural arteriovenous fistula of the cavernous sinus. ( 27194169 )
2016

Variations for Acromegaly

ClinVar genetic disease variations for Acromegaly:

6 (show all 17)
id Gene Variation Type Significance SNP ID Assembly Location
1 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh37 Chromosome 11, 67250669: 67250669
2 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh37 Chromosome 11, 67257508: 67257508
3 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh37 Chromosome 11, 67258381: 67258381
4 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh37 Chromosome 11, 67250695: 67250700
5 AIP NM_003977.3(AIP): c.824dupA (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh37 Chromosome 11, 67258295: 67258295
6 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh37 Chromosome 11, 67257582: 67257582
7 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh37 Chromosome 11, 67258275: 67258275
8 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh37 Chromosome 11, 67250693: 67250693
9 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
10 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
11 GNAS NM_000516.5(GNAS): c.680A> G (p.Gln227Arg) single nucleotide variant Pathogenic rs121913494 GRCh37 Chromosome 20, 57484596: 57484596
12 GNAS NM_000516.5(GNAS): c.601C> A (p.Arg201Ser) single nucleotide variant Pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
13 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh37 Chromosome 11, 67254618: 67254618
14 AIP NM_003977.3(AIP): c.721A> G (p.Lys241Glu) single nucleotide variant Pathogenic rs267606573 GRCh37 Chromosome 11, 67257862: 67257862
15 AIP NM_003977.3(AIP) duplication Pathogenic rs267606578 GRCh37 Chromosome 11, 67258276: 67258296
16 AIP NM_003977.3(AIP): c.811C> T (p.Arg271Trp) single nucleotide variant Pathogenic rs267606579 GRCh37 Chromosome 11, 67258282: 67258282
17 CDH23 NM_022124.5(CDH23): c.6344G> A (p.Arg2115His) single nucleotide variant Pathogenic GRCh37 Chromosome 10, 73553029: 73553029

Expression for Acromegaly

Search GEO for disease gene expression data for Acromegaly.

Pathways for Acromegaly

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 GH1 GHR GHRH GNAS IGF1 IGF2
2
Show member pathways
12.97 GH1 GHR GHRH GHRL GNAS POMC
3
Show member pathways
12.85 GH1 GHRH GNAS IGF1 IGF2 INS
4 12.47 GH1 GHR GNAS IGF1 INS PRL
5
Show member pathways
12.2 IGF1 IGF2 IGFBP1 IGFBP3
6
Show member pathways
12.08 GHRL GNAS SSTR2 SSTR5
7
Show member pathways
11.91 GH1 GHRL IGF1 INS POMC
8 11.69 IGF1 IGFBP3 INS
9 11.41 GH1 GHRH GNAS IGF1 IGF2
10 11.33 IGF1 IGF2 INS
11 11.28 GNAS IGF1 INS
12 11.27 GH1 GHR IGF1 IGF2
13
Show member pathways
11.16 GH1 GHR PRL
14 10.25 IGF1 IGF2 IGFBP1 IGFBP3

GO Terms for Acromegaly

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.77 GHRL IGFBP1 IGFBP3 INS MEN1
2 extracellular space GO:0005615 9.7 GH1 GHR GHRH GHRL IGF1 IGF2
3 extracellular region GO:0005576 9.47 GH1 GHR GHRH GHRL GNAS IGF1
4 insulin-like growth factor ternary complex GO:0042567 9.4 IGF1 IGFBP3
5 endosome lumen GO:0031904 9.33 GH1 INS PRL
6 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
7 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 insulin receptor signaling pathway GO:0008286 9.79 IGF2 IGFBP1 INS
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 GH1 IGF1 INS
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 GH1 GHR IGF1
4 glucose metabolic process GO:0006006 9.76 GHRL IGF2 INS
5 positive regulation of MAPK cascade GO:0043410 9.76 IGF1 IGF2 IGFBP3 INS
6 cell-cell signaling GO:0007267 9.7 GHRH GPR101 INS POMC SST SSTR2
7 hormone-mediated signaling pathway GO:0009755 9.69 GHR GHRL TRH
8 regulation of multicellular organism growth GO:0040014 9.67 GHR IGF1 PRL
9 positive regulation of mitotic nuclear division GO:0045840 9.65 IGF1 IGF2 INS
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 GH1 GHR IGF1 IGF2 INS
11 insulin-like growth factor receptor signaling pathway GO:0048009 9.63 GHR IGF1
12 positive regulation of insulin receptor signaling pathway GO:0046628 9.62 IGF2 INS
13 positive regulation of multicellular organism growth GO:0040018 9.62 GH1 GHR GHRH GHRL
14 positive regulation of growth hormone secretion GO:0060124 9.61 GHRH GHRL
15 positive regulation of JAK-STAT cascade GO:0046427 9.61 GH1 GHR PRL
16 growth hormone receptor signaling pathway GO:0060396 9.58 GH1 GHR
17 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 IGF2 INS
18 growth hormone secretion GO:0030252 9.57 GHRH GHRL
19 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.56 IGFBP1 IGFBP3
20 negative regulation of feeding behavior GO:2000252 9.55 INS TRH
21 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.54 GH1 GHR PRL
22 somatostatin signaling pathway GO:0038170 9.52 SSTR2 SSTR5
23 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
24 cellular protein metabolic process GO:0044267 9.17 IGF1 IGF2 IGFBP1 IGFBP3 INS MEN1
25 G-protein coupled receptor signaling pathway GO:0007186 10.08 GHRL GNAS GPR101 INS SST SSTR2
26 negative regulation of cell proliferation GO:0008285 10 IGFBP3 MEN1 SST SSTR2 SSTR5

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.5 IGF1 IGF2 INS
2 insulin-like growth factor I binding GO:0031994 9.43 IGFBP1 IGFBP3
3 insulin-like growth factor II binding GO:0031995 9.4 IGFBP1 IGFBP3
4 somatostatin receptor activity GO:0004994 9.37 SSTR2 SSTR5
5 hormone activity GO:0005179 9.28 GH1 GHRL IGF1 IGF2 INS POMC
6 prolactin receptor binding GO:0005148 9.26 GH1 PRL
7 insulin-like growth factor receptor binding GO:0005159 9.26 GNAS IGF1 IGF2 INS
8 growth hormone-releasing hormone activity GO:0016608 9.16 GHRH GHRL

Sources for Acromegaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....